Mulberry leaf reduces oxidation and C-reactive protein level in patients with mild dyslipidemia

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Aramwit, Pornanong ^a   Supasyndh, Ouppatham ^b   Siritienthong, Tippawan ^a   Bang, Nipaporn ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; C REACTIVE PROTEIN; GLUTATHIONE PEROXIDASE; LOW DENSITY LIPOPROTEIN; MULBERRY EXTRACT; TRIACYLGLYCEROL; ANTIOXIDANT;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MULBERRY; OXIDATION; PLANT LEAF; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; DYSLIPIDEMIAS; ERYTHROCYTE; METABOLISM; MIDDLE AGED; MORUS; OXIDATION REDUCTION REACTION; PHYTOTHERAPY; TIME; DRUG EFFECT;

ADULT; ANTIOXIDANTS; C-REACTIVE PROTEIN; DYSLIPIDEMIAS; ERYTHROCYTES; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MORUS; OXIDATION-REDUCTION; PHYTOTHERAPY; PLANT LEAVES; TIME FACTORS; TRIGLYCERIDES;

EID: 84874600147     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/787981     Document Type: Article

References (42)

1. Kang T. H., Hur J. Y., Kim H. B., Ryu J. H., Kim S. Y., Neuroprotective effects of the cyanidin-3-O-beta-d-glucopyranoside isolated from mulberry fruit against cerebral ischemia. Neuroscience Letters 2006 391 3 122 126 2-s2.0-33644818679
2. Park M. Y., Lee K. S., Sung M. K., Effects of dietary mulberry, Korean red ginseng, and banaba on glucose homeostasis in relation to PPAR- α PPAR- γ and LPL mRNA expressions. Life Sciences 2005 77 26 3344 3354 2-s2.0-26444562863 10.1016/j.lfs.2005.05.043 (Pubitemid 41434077)
3. Aramwit P., Petcharat K., Supasyndh O., Efficacy of mulberry leaf tablets in patients with mild dyslipidemia. Phytotherapy Research 2011 25 3 365 369 2-s2.0-79952203644 10.1002/ptr.3270
4. Enkhmaa B., Shiwaku K., Katsube T., Kitajima K., Anuurad E., Yamasaki M., Yamane Y., Mulberry (Morus alba L.) leaves and their major flavonol quercetin 3-(6-malonylglucoside) attenuate atherosclerotic lesion development in LDL receptor-deficient mice. Journal of Nutrition 2005 135 4 729 734 2-s2.0-16244395503 (Pubitemid 40464095)
5. Harauma A., Murayama T., Ikeyama K., Sano H., Arai H., Takano R., Kita T., Hara S., Kamei K., Yokode M., Mulberry leaf powder prevents atherosclerosis in apolipoprotein E-deficient mice. Biochemical and Biophysical Research Communications 2007 358 3 751 756 2-s2.0-34249084237 10.1016/j.bbrc.2007.04.170 (Pubitemid 46802455)
6. Shibata Y., Kume N., Arai H., Hayashida K., Inui-Hayashida A., Minami M., Mukai E., Toyohara M., Harauma A., Murayama T., Kita T., Hara S., Kamei K., Yokode M., Mulberry leaf aqueous fractions inhibit TNF- α -induced nuclear factor B (NF- B) activation and lectin-like oxidized LDL receptor-1 (LOX-1) expression in vascular endothelial cells. Atherosclerosis 2007 193 1 20 27 2-s2.0-34248670397 10.1016/j.atherosclerosis.2006.08.011 (Pubitemid 46776706)
7. Sritara P., Cheepudomwit S., Chapman N., Woodward M., Kositchaiwat C., Tunlayadechanont S., Sura T., Hengprasith B., Tanphaichitr V., Lochaya S., Neal B., Tanomsup S., Yipintsoi T., Twelve-year changes in vascular risk factors and their associations with mortality in a cohort of 3499 Thais: The Electricity Generating Authority of Thailand study. International Journal of Epidemiology 2003 32 3 461 468 2-s2.0-0037967248 (Pubitemid 36764108)
8. Tatsanavivat P., Klungboonkrong V., Chirawatkul A., Bhuripanyo K., Manmontri A., Chitanondh H., Yipintsoi T., Prevalence of coronary heart disease and major cardiovascular risk factors in Thailand. International Journal of Epidemiology 1998 27 3 405 409 2-s2.0-0031843939 10.1093/ije/27.3.405 (Pubitemid 28336966)
9. Witztum J. L., Steinberg D., The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends in Cardiovascular Medicine 2001 11 3-4 93 102 2-s2.0-0035176943 10.1016/S1050-1738(01)00111-6 (Pubitemid 33070331)
10. Gaut J. P., Heinecke J. W., Mechanisms for oxidizing low-density lipoprotein: insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. Trends in Cardiovascular Medicine 2001 11 3-4 103 112 2-s2.0-0035181940 10.1016/S1050-1738(01)00101-3 (Pubitemid 33070332)
11. Ohara Y., Peterson T. E., Sayegh H. S., Subramanian R. R., Wilcox J. N., Harrison D. G., Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation 1995 92 4 898 903 2-s2.0-0029118174
12. Reilly M. P., Praticó D., Delanty N., DiMinno G., Tremoli E., Rader D., Kapoor S., Rokach J., Lawson J., FitzGerald G. A., Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 1998 98 25 2822 2828 2-s2.0-0032578979 (Pubitemid 29003962)
13. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L., Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. The New England Journal of Medicine 1989 320 14 915 924 2-s2.0-0024603895 (Pubitemid 19101597)
14. Singhania N., Puri D., Madhu S. V., Sharma S. B., Assessment of oxidative stress and endothelial dysfunction in Asian Indians with type 2 diabetes mellitus with and without macroangiopathy. QJM 2008 101 6 449 455 2-s2.0-44849132023 10.1093/qjmed/hcn020 (Pubitemid 351791528)
15. Chen H., Yu M., Li M., Zhao R., Zhu Q., Zhou W., Lu M., Lu Y., Zheng T., Jiang J., Zhao W., Xiang K., Jia W., Liu L., Polymorphic variations in manganese superoxide dismutase (MnSOD), glutathione peroxidase-1 (GPX1), and catalase (CAT) contribute to elevated plasma triglyceride levels in Chinese patients with type 2 diabetes or diabetic cardiovascular disease. Molecular and Cellular Biochemistry 2012 363 185 291
16. Black S., Kushner I., Samols D., C-reactive protein. Journal of Biological Chemistry 2004 279 47 48487 48490 2-s2.0-10344239447 10.1074/jbc.R400025200 (Pubitemid 39625721)
17. Libby P., Ridker P. M., Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. American Journal of Medicine 2004 116 6 9 16 2-s2.0-1642545106 10.1016/j.amjmed.2004.02.006 (Pubitemid 38402010)
18. Pasceri V., Willerson J. T., Yeh E. T. H., Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000 102 18 2165 2168 2-s2.0-0034739462
19. Rifai N., Tracy R. P., Ridker P. M., Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clinical Chemistry 1999 45 12 2136 2141 2-s2.0-0032710356
20. Ridker P. M., Hennekens C. H., Buring J. E., Rifai N., C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. The New England Journal of Medicine 2000 342 12 836 843 2-s2.0-0034704893 10.1056/NEJM200003233421202 (Pubitemid 30165206)
21. Ridker P. M., Buring J. E., Rifai N., Cook N. R., Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. Journal of the American Medical Association 2007 297 6 611 619 2-s2.0-33846996345 10.1001/jama.297.6.611
22. Pearson T. A., Mensah G. A., Alexander R. W., Anderson J. L., Cannon R. O., Criqui M., Fadl Y. Y., Fortmann S. P., Hong Y., Myers G. L., Rifai N., Smith S. C., Taubert K., Tracy R. P., Vinicor F., Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003 107 3 499 511 2-s2.0-0037469232 10.1161/01.CIR.0000052939.59093.45 (Pubitemid 36158056)
23. Ridker P. M., MacFadyen J., Libby P., Glynn R. J., Relation of baseline high-sensitivity c-reactive protein level to cardiovascular outcomes with rosuvastatin in the justification for use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). American Journal of Cardiology 2010 106 2 204 209 2-s2.0-77955711541 10.1016/j.amjcard.2010.03.018
24. Blois M. S., Antioxidant determinations by the use of a stable free radical. Nature 1958 181 4617 1199 1200 2-s2.0-36949063535 10.1038/1811199a0
25. Grundy S. M., Cleeman J. I., Merz C. N., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 110 2 227 239 2-s2.0-3142729178 10.1161/01.CIR.0000133317.49796.0E (Pubitemid 38924592)
26. Paglia D. E., Valentine W. N., Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. The Journal of Laboratory and Clinical Medicine 1967 70 1 158 169 2-s2.0-0014108436
27. Jacobson B., Quigley G., Lockitch G., Adaptation of glutathione peroxidase assay to the Technicon RA-1000. Clinical Chemistry 1988 34 10 2164 2165 2-s2.0-0024095727
28. Danesh J., Wheeler J. G., Hirschfield G. M., Eda S., Eiriksdottir G., Rumley A., Lowe G. D. O., Pepys M. B., Gudnason V., C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. The New England Journal of Medicine 2004 350 14 1387 1397 2-s2.0-1842587885 10.1056/NEJMoa032804 (Pubitemid 38419992)
29. Koenig W., Khuseyinova N., Baumert J., Thorand B., Loewel H., Chambless L., Meisinger C., Schneider A., Martin S., Kolb H., Herder C., Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 12 2745 2751 2-s2.0-33751191631 10.1161/01.ATV.0000248096.62495.73
30. Lloyd-Jones D. M., Liu K., Tian L., Greenland P., Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Annals of Internal Medicine 2006 145 1 35 42 2-s2.0-33745966838 (Pubitemid 46780605)
31. Coventry B. J., Ashdown M. L., Quinn M. A., Markovic S. N., Yatomi-Clarke S. L., Robinson A. P., CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? Journal of Translational Medicine 2009 7, article 102 2-s2.0-72549117233 10.1186/1479-5876-7-102
32. Hermsdorff H. H., Volp A. C., Puchau B., Barbosa K. B., Zulet M. A., Bressan J., Martinez J. A., Contribution of gender and body fat distribution to inflammatory marker concentrations in apparently healthy young adults. Inflammation Research 2012 61 5 427 435
33. Choi J., Joseph L., Pilote L., Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obesity Reviews. In press
34. Naowaboot J., Pannangpetch P., Kukongviriyapan V., Kongyingyoes B., Kukongviriyapan U., Antihyperglycemic, antioxidant and antiglycation activities of mulberry leaf extract in streptozotocin-induced chronic diabetic rats. Plant Foods for Human Nutrition 2009 64 2 116 121 2-s2.0-70349316672 10.1007/s11130-009-0112-5
35. Naowaratwattana W., De-Eknamkul W., De Mejia E. G., Phenolic-containing organic extracts of mulberry (Morus alba L.) leaves inhibit HepG2 hepatoma cells through G2/M phase arrest and inhibition of topoisomerase II α activity. Journal of Medicinal Food 2010 13 5 1045 1056 2-s2.0-77956574025 10.1089/jmf.2010.1021
36. Vigushin D. M., Pepys M. B., Hawkins P. N., Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. Journal of Clinical Investigation 1993 91 4 1351 1357 2-s2.0-0027316064 (Pubitemid 23127332)
37. Benitz W. E., Han M. Y., Madan A., Ramachandra P., Serial serum C-reactive protein levels in the diagnosis of neonatal infection. Pediatrics 1998 102 4 E41 2-s2.0-0032185465
38. Glass C. K., Witztum J. L., Atherosclerosis: the road ahead. Cell 2001 104 4 503 516 2-s2.0-0035936802 10.1016/S0092-8674(01)00238-0 (Pubitemid 32201946)
39. Guo Z., Van Remmen H., Yang H., Chen X., Mele J., Vijg J., Epstein C. J., Ho Y. S., Richardson A., Changes in expression of antioxidant enzymes affect cell-mediated LDL oxidation and oxidized LDL-induced apoptosis in mouse aortic cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 7 1131 1138 2-s2.0-0035720442 (Pubitemid 34215140)
40. Lapenna D., De Gioia S., Ciofani G., Mezzetti A., Ucchino S., Calafiore A. M., Napolitano A. M., Ilio C. D., Cuccurullo F., Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation 1998 97 19 1930 1934 2-s2.0-0032546647 (Pubitemid 28222187)
41. Milne G. L., Musiek E. S., Morrow J. D., F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers 2005 10 supplement 1 S10 23 2-s2.0-33645569222
42. Sciascia S., Roccatello D., Bertero M. T., 8- isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study. Inflammation Research 2012 61 8 809 816